Fulgent Genetics Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Fulgent Genetics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FLGT, but not buy additional shares or sell existing shares.
View analyst ratings for Fulgent Genetics or view top-rated stocks.

Wall Street analysts have given Fulgent Genetics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fulgent Genetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Fulgent Genetics saw a drop in short interest in the month of August. As of August 13th, there was short interest totaling 3,850,000 shares, a drop of 14.3% from the July 29th total of 4,490,000 shares. Based on an average daily volume of 754,000 shares, the short-interest ratio is currently 5.1 days. Currently, 20.2% of the shares of the stock are short sold.
View Fulgent Genetics' Short Interest.

Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for Fulgent Genetics.

Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings data on Monday, August, 9th. The company reported $2.47 EPS for the quarter, missing the Zacks' consensus estimate of $2.54 by $0.07. The firm earned $153.60 million during the quarter, compared to analyst estimates of $197.34 million. Fulgent Genetics had a trailing twelve-month return on equity of 78.71% and a net margin of 54.24%. The business's revenue was up 789.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.19 earnings per share.
View Fulgent Genetics' earnings history.

Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FLGT stock has increased by 756.8% and is now trading at $86.19.
View which stocks have been most impacted by COVID-19.

Fulgent Genetics issued an update on its third quarter 2021 earnings guidance on Monday, September, 6th. The company provided EPS guidance of for the period. The company issued revenue guidance of $125 million-$150 million, compared to the consensus revenue estimate of $146.10 million.

5 equities research analysts have issued 1-year price objectives for Fulgent Genetics' shares. Their forecasts range from $42.00 to $140.00. On average, they anticipate Fulgent Genetics' share price to reach $94.25 in the next year. This suggests a possible upside of 9.4% from the stock's current price.
View analysts' price targets for Fulgent Genetics or view top-rated stocks among Wall Street analysts.

Some companies that are related to Fulgent Genetics include Invitae (NVTA), Elekta AB (publ) (EKTAY), CareDx (CDNA), Veracyte (VCYT), Burning Rock Biotech (BNR), Castle Biosciences (CSTL), RadNet (RDNT), Genetron (GTH), DermTech (DMTK), Personalis (PSNL), Renalytix AI (RNLX), Celcuity (CELC), Sera Prognostics (SERA), Exagen (XGN) and Centogene (CNTG).
View all of FLGT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Inseego (INSG), NeoGenomics (NEO), Invitae (NVTA), Square (SQ), JD.com (JD), Marvell Technology (MRVL), Teladoc Health (TDOC) and Editas Medicine (EDIT).

(FLGT) raised $60 million in an initial public offering on Thursday, September 29th 2016. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.

Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."

Fulgent Genetics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.54%), Vanguard Group Inc. (4.41%), State Street Corp (2.10%), Susquehanna International Group LLP (0.00%), Morgan Stanley (1.25%) and Morgan Stanley (1.23%). Company insiders that own Fulgent Genetics stock include Hanlin Gao, Jian Xie, John C Bolger, Paul Kim and X Cycle LP Tcv.
View institutional ownership trends for Fulgent Genetics.

FLGT stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Morgan Stanley, Morgan Stanley, Citadel Advisors LLC, Russell Investments Group Ltd., Millennium Management LLC, Marshall Wace LLP, and Marshall Wace LLP. Company insiders that have sold Fulgent Genetics company stock in the last year include Hanlin Gao, Jian Xie, John C Bolger, and Paul Kim.
View insider buying and selling activity for Fulgent Genetics or view top insider-selling stocks.

FLGT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., JPMorgan Chase & Co., State Street Corp, Capital Fund Management S.A., Geode Capital Management LLC, First Trust Advisors LP, and Skandinaviska Enskilda Banken AB publ.
View insider buying and selling activity for Fulgent Genetics or or view top insider-buying stocks.

Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FLGT stock can currently be purchased for approximately $86.19.

Fulgent Genetics has a market capitalization of $2.54 billion and generates $421.71 million in revenue each year. The company earns $214.31 million in net income (profit) each year or $8.85 on an earnings per share basis.

Fulgent Genetics employs 429 workers across the globe.

The official website for Fulgent Genetics is www.fulgentgenetics.com.

Fulgent Genetics is headquartered at 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780.

Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The company can be reached via phone at (626) 350-0537 or via email at [email protected]